Chemotherapy in Patients with Hepatobiliary Cancers and Abnormal Hepatic Function

Overview

Journal J Gastrointest Oncol

Date 2017 May 9

PMID 28480070

Citations 5

Authors

Jun Gong

May Cho

Marwan Fakih

Affiliations

Soon will be listed here.

Abstract

Sorafenib and cisplatin plus gemcitabine currently represent first-line treatment standards in advanced hepatocellular carcinoma and biliary cancer, respectively. Conventional cytotoxic agents (monotherapy or combination therapy) have demonstrated activity in the second-line setting or in those in which first-line agents are contraindicated. A strategy for safe yet effective administration of such systemic therapies in patients with advanced hepatobiliary cancer and abnormal liver function needs to be strongly considered. Here, we highlight the safety and tolerability of systemic therapies routinely used for the treatment of advanced hepatobiliary cancer in patients with hepatic dysfunction. Based on data from available clinical studies, we review dosing strategies recommended for chemotherapy and targeted therapy in those with liver dysfunction. Dose modifications for many agents in this population remain empiric due to limited clinical evidence. Future dedicated phase I studies are needed to provide further dosing considerations for combination therapy in those with abnormal liver function in which data is lacking.

Citing Articles

Improved Survival With Chemotherapy in Patients With Malignant Biliary Tract Obstruction After Percutaneous Transhepatic Biliary Drainage (PTBD).

Jagtap V, Kumar S, Harris C, Lynser D, Raphael V Cureus. 2024; 16(6):e63218.

PMID: 39070492 PMC: 11279073. DOI: 10.7759/cureus.63218.

Long-term survival outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of hepatocellular carcinoma patients.

Yan G, Zhang K, Yan L, Zhang Y World J Surg Oncol. 2024; 22(1):144.

PMID: 38822337 PMC: 11140955. DOI: 10.1186/s12957-024-03426-1.

Optimal liver drainage rate for survival in patients with unresectable malignant hilar biliary obstruction using 3D-image volume analyzer.

Morimoto K, Matsumoto K, Obata T, Oda T, Miyamoto K, Matsumi A Therap Adv Gastroenterol. 2023; 16:17562848231206980.

PMID: 37900006 PMC: 10612458. DOI: 10.1177/17562848231206980.

Nationwide treatment and outcomes of perihilar cholangiocarcinoma.

van Keulen A, Franssen S, van der Geest L, de Boer M, Coenraad M, van Driel L Liver Int. 2021; 41(8):1945-1953.

PMID: 33641214 PMC: 8359996. DOI: 10.1111/liv.14856.

Albumin-Bilirubin Score Predicts Tolerability to Adjuvant S-1 Monotherapy after Curative Gastrectomy.

Miwa T, Kanda M, Tanaka C, Kobayashi D, Hayashi M, Yamada S J Gastric Cancer. 2019; 19(2):183-192.

PMID: 31245163 PMC: 6589428. DOI: 10.5230/jgc.2019.19.e15.

References

Shimura T, Kataoka H, Hirata Y, Mizushima T, Murakami K, Mabuchi M . Metastatic colorectal cancer with severe liver dysfunction successfully treated using FOLFOX therapy. J Gastrointest Cancer. 2010; 42(1):68-72. DOI: 10.1007/s12029-010-9176-6. View

Miller A, Murry D, Owzar K, Hollis D, Kennedy E, Abou-Alfa G . Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009; 27(11):1800-5. PMC: 2668705. DOI: 10.1200/JCO.2008.20.0931. View

Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-81. DOI: 10.1056/NEJMoa0908721. View

Poplin E, Roberts J, Tombs M, Grant S, Rubin E . Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study. Invest New Drugs. 1999; 17(1):57-62. DOI: 10.1023/a:1006239200772. View

Venook A, Egorin M, Rosner G, Hollis D, Mani S, Hawkins M . Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000; 18(14):2780-7. DOI: 10.1200/JCO.2000.18.14.2780. View

Synold T, Takimoto C, Doroshow J, Gandara D, Mani S, Remick S . Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2007; 13(12):3660-6. DOI: 10.1158/1078-0432.CCR-06-2385. View

Alberts S, Al-Khatib H, Mahoney M, Burgart L, Cera P, Flynn P . Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer. 2004; 103(1):111-8. DOI: 10.1002/cncr.20753. View

Field K, Dow C, Michael M . Part I: Liver function in oncology: biochemistry and beyond. Lancet Oncol. 2008; 9(11):1092-101. DOI: 10.1016/S1470-2045(08)70279-1. View

Gebbia V, Giuliani F, Maiello E, Colucci G, Verderame F, Borsellino N . Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol. 2001; 19(20):4089-91. DOI: 10.1200/JCO.2001.19.20.4089. View

10.

He S, Shen J, Sun X, Liu L, Dong J . A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. J Chemother. 2013; 26(4):243-7. DOI: 10.1179/1973947813Y.0000000133. View

11.

Hwang S, Park J, Lee S, Kim G, Sin C, Nam S . Capecitabine and oxaliplatin (XELOX) for the treatment of patients with metastatic gastric cancer and severe liver dysfunction. Korean J Intern Med. 2007; 21(4):252-5. PMC: 3891032. DOI: 10.3904/kjim.2006.21.4.252. View

12.

Roderburg C, do O N, Fuchs R, Bubenzer J, Spannbauer M, Luedde T . Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction. Clin Colorectal Cancer. 2011; 10(1):E6-9. DOI: 10.3816/CCC.2011.n.011. View

13.

Elsoueidi R, Craig J, Mourad H, Richa E . Safety and efficacy of FOLFOX followed by cetuximab for metastatic colorectal cancer with severe liver dysfunction. J Natl Compr Canc Netw. 2014; 12(2):155-60. DOI: 10.6004/jnccn.2014.0016. View

14.

Fakih M . 5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction. Oncology. 2004; 67(3-4):222-4. DOI: 10.1159/000081321. View

15.

Schaaf L, Hammond L, Tipping S, Goldberg R, Goel R, Kuhn J . Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction. Clin Cancer Res. 2006; 12(12):3782-91. DOI: 10.1158/1078-0432.CCR-05-2152. View

16.

Berlin J, Alberti D, Arzoomanian R, Feierabend C, Simon K, Binger K . A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors. Invest New Drugs. 1999; 16(4):325-30. DOI: 10.1023/a:1006242005837. View

17.

Joerger M, Huitema A, Koeberle D, Rosing H, Beijnen J, Hitz F . Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemother Pharmacol. 2013; 73(1):113-24. DOI: 10.1007/s00280-013-2327-2. View

18.

Andre T, Reyes-Vidal J, Fartoux L, Ross P, Leslie M, Rosmorduc O . Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2009; 99(6):862-7. PMC: 2538748. DOI: 10.1038/sj.bjc.6604628. View

19.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

20.

Lamarca A, Benafif S, Ross P, Bridgewater J, Valle J . Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. Eur J Cancer. 2015; 51(13):1694-703. DOI: 10.1016/j.ejca.2015.05.018. View